Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A set of circulating microRNAs belonging to the 14q32 chromosomic locus identifies two different subgroups of individuals with recent onset Stage 3 type 1 diabetes [first cohort, targeted]

ABSTRACT: A set of circulating microRNAs belonging to the 14q32 chromosomic locus identifies two different subgroups of individuals with recent onset Stage 3 type 1 diabetes [first cohort, targeted]

PROVIDER: PRJNA1105079 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR28816300.fastq.gz	Fastqsanger.gz
	SRR28816301.fastq.gz	Fastqsanger.gz
	SRR28816302.fastq.gz	Fastqsanger.gz
	SRR28816303.fastq.gz	Fastqsanger.gz
	SRR28816304.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 119

Similar Datasets

A set of circulating microRNAs belonging to the 14q32 chromosomic locus identifies two different subgroups of individuals with recent onset Stage 3 type 1 diabetes [second cohort, untargeted]

Project description:Circulating microRNAs are linked to the onset and progression of type 1 diabetes mellitus (T1DM), making them potential biomarkers for the disease. In this study, we employ a multiplatform sequencing approach to analyze circulating microRNAs in an extended cohort of individuals with T1DM from the INNODIA consortium. Our findings reveal that a set of microRNAs located within the T1DM susceptibility chromosomal locus 14q32 distinguishes two subgroups of individuals. To validate our results, we conduct additional analyses on a second cohort of T1DM individuals, confirming the identification of these subgroups, which we have named Cluster A and Cluster B. Remarkably, Cluster B T1DM individuals, who exhibit increased expression of a set of 14q32 miRNAs, show better glycaemic control and display a different blood immunomics profile. Our findings suggest that this set of circulating microRNAs can identify two different T1DM subgroups with distinct blood immunomics at baseline and clinical outcomes during follow-up.

2024-05-03 | GSE265981 | GEO

A set of circulating microRNAs belonging to the 14q32 chromosomic locus identifies two different subgroups of individuals with recent onset Stage 3 type 1 diabetes [first cohort, untargeted]

2024-05-03 | GSE265980 | GEO

A set of circulating microRNAs belonging to the 14q32 chromosomic locus identifies two different subgroups of individuals with recent onset Stage 3 type 1 diabetes [first cohort, targeted]

2024-05-03 | GSE265976 | GEO

A set of circulating microRNAs belonging to the 14q32 chromosomic locus identifies two different subgroups of individuals with recent onset Stage 3 type 1 diabetes [first cohort, untargeted]

Project description:A set of circulating microRNAs belonging to the 14q32 chromosomic locus identifies two different subgroups of individuals with recent onset Stage 3 type 1 diabetes [first cohort, untargeted]

| PRJNA1105085 | ENA

A set of circulating microRNAs belonging to the 14q32 chromosomic locus identifies two different subgroups of individuals with recent onset Stage 3 type 1 diabetes [second cohort, untargeted]

| PRJNA1105084 | ENA

Peripheral Blood Monocyte Gene Expression in Recent-Onset Type 1 Diabetes

Project description:OBJECTIVE: Novel biomarkers of disease progression after type 1 diabetes onset are needed. RESEARCH DESIGN AND METHODS: We profiled peripheral blood (PB) monocyte gene expression in 6 healthy subjects and 16 children with type 1 diabetes diagnosed ~3 months previously, and analyzed clinical features from diagnosis to 1 year. RESULTS: Monocyte expression profiles clustered into two distinct subgroups, representing mild and severe deviation from healthy controls, along the same continuum. Patients with strongly divergent monocyte gene expression had significantly higher insulin dose-adjusted HbA1c levels during the first year, compared to patients with mild deviation. The diabetes-associated expression signature identified multiple perturbations in pathways controlling cellular metabolism and survival, including endoplasmic reticulum and oxidative stress (e.g. induction of HIF1A, DDIT3, DDIT4 and GRP78). qPCR quantitation of a 9-gene panel correlated with glycaemic control in 12 additional recent-onset patients. The qPCR signature was also detected in PB from healthy first-degree relatives. CONCLUSIONS: A PB gene expression signature correlates with glycaemic control in the first year after diabetes diagnosis, and is present in at-risk subjects. These findings implicate monocyte phenotype as a candidate biomarker for disease progression pre- and post-onset, and systemic stresses as contributors to innate immune function in type 1 diabetes. CD14+ monocytes from a total of 16 children with recent-onset type 1 diabetes and 6 adult healthy controls were profiled in 2 independent microarrays.

2012-05-31 | E-GEOD-33440 | biostudies-arrayexpress

Deregulated Expression of the 14q32 miRNA Cluster in Clear Cell Renal Cell Carcinomas

Project description:Clear cell renal cell carcinomas (ccRCC) are characterized by arm-wide chromosomal alterations. Loss at 14q is associated with disease aggressiveness in ccRCC, which responds poorly to chemotherapeutics. The 14q locus contains one of the largest miRNA clusters in the human genome; however, little is known about the contribution of these miRNAs to ccRCC pathogenesis. In this regard, we investigated the expression pattern of selected miRNAs at the 14q32 locus in TCGA kidney tumors and in ccRCC cell lines. We validated that the miRNA cluster is downregulated in ccRCC (and cell lines) as well as in papillary kidney tumors relative to normal kidney tissues and primary renal proximal tubule epithelial (RPTEC) cells. We demonstrated that agents modulating expression of DNMT1 (e.g., 5-Aza-deoxycytidine) could modulate miRNA expression in ccRCC cell lines. Lysophosphatidic acid (LPA, a Lysophospholipid mediator elevated in ccRCC) not only increased labile iron content but also modulated expression of 14q32 miRNAs. Through an overexpression approach targeting a subset of 14q32 miRNAs (specifically at subcluster A: miR-431, miR-432, miR-127, and miR-433) in 769-P cells, we uncovered changes in cellular viability and claudin-1, a tight junction marker. A global proteomic approach was implemented using these miRNA overexpressing cell lines which uncovered ATXN2 as a highly downregulated target, which has a role in chronic kidney disease pathogenesis. Collectively, these findings support a contribution of miRNAs at 14q32 in ccRCC pathogenesis.

2023-05-10 | PXD036428 | Pride

Modulation of gene expression after inducing expression of 14q32 miRNAs by CRISPR activation technology in lung adenocarcinoma

Project description:Most lung adenocarcinoma deaths are related to metastases, indicating the necessity of detecting and inhibiting tumor cell dissemination. We have identified that overexpression of miRNAs located on 14q32 was associated with metastasis in lung adenocarcinoma patients. For functional analysis, we utilized CRISPR activation technology to increase levels of miRNAs clustered on 14q32 in a coordinated manner, and the results showed that 14q32 miRNA overexpression promoted tumor cell migratory and invasive properties. Whole transcriptome microarray analysis of the miRNA-overexpressing cells was performed to define the underlying molecular mechanisms. Microarray analysis was used to investigate the gene expression changes underlying the tumor cell migratory and invasive properties induced by 14q32 miRNAs in lung adenocarcinoma.

2018-03-12 | GSE99050 | GEO

Epigenome analysis of normal and recent onset psychosis samples

Project description:Genome wide DNA methylation profiling of normal and recent onset psychosis samples . The Infinium Human Methylation 850 K BeadChips was used to obtain DNA methylation profiles across approximately 853 307 CpGs in samples. Samples included 50 normal , 84 recent onset psychosis.

2020-09-02 | GSE157252 | GEO

Peripheral Blood Monocyte Gene Expression in Recent-Onset Type 1 Diabetes

2012-06-01 | GSE33440 | GEO